|
Shchemeleva E.V., Skorodumova E.A.
Febuxostat: Efficacy and safety of the drug, prospects for application (literature review)
|
№5 / 2024
|
|
Eliseev M.S.
What we know about gout today
|
№1 / 2024
|
|
Garanin A.A., Lebedev P.A., Paranina E.V.
Hereditary gout in a young woman with allopurinol intolerance
|
№6 / 2023
|
|
Gaydukova I.Z., Mazurov V.I., Inamova O.V., Zinserling A.Yu., Bashkinov R.A.
Increasing of glomeral filtration rate in the setting of serum uric acid normalization in high cardiovascular risk patients – clinical observations
|
№3 / 2023
|
|
Panevin T.S., Eliseev M.S., Bobkova A.O., Dimitreva A.E., Urumova M.M.
Use of dapagliflozin in a comorbid patient: new opportunities
|
№3 / 2023
|
|
Shchemeleva E.V., Skorodumova E.A.
Adherence to therapy in patients with gout
|
№8 / 2021
|
|
Pereverzev A.P., Ostroumova O.D.
Drug-induced hyperuricemia/gout. Part 1: prevalence, pathophysiology, risk factors, clinical pattern
|
№6 / 2021
|
|
Mazurov V.I., Petrova M.S., Gaydukova I.Z., Inamova O.V., Fonturenko A.Yu., Gaydukova E.K., Shapovalov A.A., Nagirnyak I.M.
Features of gouty arthritis according to the St. Petersburg City register of gout (2016–2018 years)
|
№6 / 2019
|
|
Georginova O.A., Gorbunov R.M., Kadrev A.V., Plisyuk A.G.
Verification difficulties of diagnosis in a patient with uratosis and pyrophosphate arthropathy
|
№3 / 2019
|
|
Gromova M.A., Tsurko V.V., Kashkadaeva A.V., Averinova S.G.
Assessment of urinary system functional reserves in the patient with gout against a background of a chronic glomerulonephritis according to complex renal scintigraphy
|
№3 / 2019
|
|
M.S. Yeliseev, O.V. Zhelyabina
Influence of plant products on the uric acid levels. Literature review
|
№4 / 2017
|
|
I.M. Marusenko, I.I. Polskaya, T.I. Kulagina, N.N. Vezikova
Metabolic syndrome in patients with gout and its impact on the risk of cardiovascular diseases
|
№3 / 2016
|
Русский
